Multiplexed MRM-based quantitation of candidate cancer biomarker proteins in undepleted and non-enriched human plasma.
about
The Role of Proteomics in Biomarker Development for Improved Patient Diagnosis and Clinical Decision Making in Prostate CancerAdvances in targeted proteomics and applications to biomedical researchIdentification and validation of potential new biomarkers for prostate cancer diagnosis and prognosis using 2D-DIGE and MS.New GO-PEI-Au-L-Cys ZIC-HILIC composites: synthesis and selective enrichment of glycopeptides.Discovery and targeted proteomics on cutaneous biopsies infected by borrelia to investigate lyme disease.Simultaneous Enrichment of Plasma Soluble and Extracellular Vesicular Glycoproteins Using Prolonged Ultracentrifugation-Electrostatic Repulsion-hydrophilic Interaction Chromatography (PUC-ERLIC) Approach.Targeted quantification of N-1-(carboxymethyl) valine and N-1-(carboxyethyl) valine peptides of β-hemoglobin for better diagnostics in diabetes.Identification of IGFBP2 and IGFBP3 As Compensatory Biomarkers for CA19-9 in Early-Stage Pancreatic Cancer Using a Combination of Antibody-Based and LC-MS/MS-Based ProteomicsAccuracy and Reproducibility in Quantification of Plasma Protein Concentrations by Mass Spectrometry without the Use of Isotopic StandardsTargeted quantification of low ng/mL level proteins in human serum without immunoaffinity depletionDevelopment of a Targeted Urine Proteome Assay for kidney diseases.Plasma Proteome Database as a resource for proteomics research: 2014 update.Pre-analytical and analytical variability in absolute quantitative MRM-based plasma proteomic studies.Mass spectrometry-based plasma proteomics: state of the art and future outlook.Colorectal cancer biomarker discovery and validation using LC-MS/MS-based proteomics in blood: truth or dare?Mass spectrometry based biomarker discovery, verification, and validation--quality assurance and control of protein biomarker assays.Neuroproteomic profiling of human body fluids.Clinical proteomics-driven precision medicine for targeted cancer therapy: current overview and future perspectives.Proteomics Research in Cardiovascular Medicine and Biomarker Discovery.Protocol for Standardizing High-to-Moderate Abundance Protein Biomarker Assessments Through an MRM-with-Standard-Peptides Quantitative Approach.Analytical performance of nano-LC-SRM using nondepleted human plasma over an 18-month period.Development of a highly automated and multiplexed targeted proteome pipeline and assay for 112 rat brain synaptic proteins.Integrative analysis for the discovery of lung cancer serological markers and validation by MRM-MS.Revisiting biomarker discovery by plasma proteomics.Identification of Borrelia protein candidates in mouse skin for potential diagnosis of disseminated Lyme borreliosis.Analysis of the plasma proteome using iTRAQ and TMT-based Isobaric labeling.Onco-proteogenomics: Multi-omics level data integration for accurate phenotype prediction.ExSTA: External Standard Addition Method for Accurate High-Throughput Quantitation in Targeted Proteomics Experiments.Development of a Multiplexed Liquid Chromatography Multiple-Reaction-Monitoring Mass Spectrometry (LC-MRM/MS) Method for Evaluation of Salivary Proteins as Oral Cancer Biomarkers.PeptideTracker: A knowledge base for collecting and storing information on protein concentrations in biological tissues.Targeted proteomics strategy applied to biomarker evaluation.A standardized kit for automated quantitative assessment of candidate protein biomarkers in human plasma.
P2860
Q26738703-DA3D6DF4-B5BA-4D70-973E-18B2B2C8D83CQ28066912-ABD36F2E-525B-4944-A8BD-7C791E9D69AEQ35033878-9C07E0DA-F65B-4341-AA86-AE35C552E64FQ35154102-6192F34D-82D1-4285-812D-7D41ADF789E7Q35583325-190C4F16-A068-4D51-934F-039FA826AF66Q35692136-67D99078-FFEA-4ADA-8561-D8B9743D3126Q35974787-FB8C0A56-B621-47F3-A97F-AF01C78007A2Q36118351-998CC473-3968-4868-B704-0B0ACC8270FDQ36170999-FF5F6E40-ABE6-47AD-BDC4-7C1957660FE9Q37069906-9E6C1A6D-A6D9-412A-9CBD-34A7C7B9BDB1Q37214750-D31AB7E4-7EEC-4B79-BB80-14136364B5D7Q37661894-67319ECE-E50C-485B-B3F8-9A644B1F48EBQ38164428-0B831DA1-EF82-4929-9C62-A7E385CB84BDQ38198753-308713EF-E9C6-4FF5-88B0-021027422222Q38202166-B6B3800E-5E97-4831-938D-15B31880FF02Q38203040-ED9B054C-BBE7-4D23-B155-95320AD51DCAQ38569255-5F3F7BB3-7482-4E82-AAA2-6A8972D9368FQ38753775-DCF08CB3-9B2E-4F3E-992C-530B03EE5017Q39050547-3AAD84F0-6EC9-472F-8191-3FAE00030E07Q39099850-ECFB683D-F26E-49CA-9919-A9839133C7E4Q39730810-A419AC8F-9A9A-4CE5-912B-C445776313E7Q41371983-AB7909B1-D9B6-4B41-89C1-0A92B2971827Q41513462-70D70B54-2156-4E85-B309-D3AD0470D6FEQ41676452-06632F5B-DDFB-4A18-B7BB-020CA5332776Q47097911-F2F1B2BD-2FD5-4985-8D4D-2435B849080CQ47421750-AFBFD1F6-DFC8-47C9-A7B0-F3380F8D0494Q47660956-B46222B9-73CC-49A8-A55F-8D075F3E5455Q47818859-B2AE3D53-6C12-454B-8EA1-DE68DBA5ADEDQ48196134-F1072807-8B38-476E-B285-D57312C3D17CQ51451193-114E161E-E1A4-43C9-B44C-33592CE537C2Q51777239-AFFC0D35-A4A7-4DB2-A368-2BA32BD6682BQ53182929-3A82D914-B0DE-4123-BE07-240A4D25A902
P2860
Multiplexed MRM-based quantitation of candidate cancer biomarker proteins in undepleted and non-enriched human plasma.
description
2013 nî lūn-bûn
@nan
2013年の論文
@ja
2013年学术文章
@wuu
2013年学术文章
@zh
2013年学术文章
@zh-cn
2013年学术文章
@zh-hans
2013年学术文章
@zh-my
2013年学术文章
@zh-sg
2013年學術文章
@yue
2013年學術文章
@zh-hant
name
Multiplexed MRM-based quantita ...... and non-enriched human plasma.
@en
Multiplexed MRM-based quantita ...... and non-enriched human plasma.
@nl
type
label
Multiplexed MRM-based quantita ...... and non-enriched human plasma.
@en
Multiplexed MRM-based quantita ...... and non-enriched human plasma.
@nl
prefLabel
Multiplexed MRM-based quantita ...... and non-enriched human plasma.
@en
Multiplexed MRM-based quantita ...... and non-enriched human plasma.
@nl
P2093
P2860
P356
P1433
P1476
Multiplexed MRM-based quantita ...... and non-enriched human plasma.
@en
P2093
Andrew G Chambers
Andrew J Percy
Christoph H Borchers
Juncong Yang
P2860
P304
P356
10.1002/PMIC.201200316
P577
2013-06-06T00:00:00Z